Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(R) therapy: A case report

Elizabete Pumpure, Eva Dručka, Dana Kigitoviča, Raimundas Meškauskas, Sergejs Isajevs, Ineta Nemiro, Agnija Rasa (Coresponding Author), Evija Olmane, Tatjana Zablocka, Pēteris Alberts, Simona Doniņa

Research output: Contribution to journalArticlepeer-review

Abstract

Primary malignant melanoma of the uterine cervix is a rare disease with poor prognosis and high recurrence rate. We used Rigvir® as adjuvant therapy for a stage IVA patient. Tolerability, overall and progression-free survival are good.

Original languageEnglish
Pages (from-to)1538-1543
Number of pages6
JournalClinical Case Reports
Volume8
Issue number8
DOIs
Publication statusPublished - 1 Aug 2020

Keywords

  • ECHO-7 virus
  • melanoma
  • oncology
  • oncolytic virus
  • Rigvir
  • uterine cervix

Field of Science

  • 3.2 Clinical medicine

Publication Type

  • 1.1. Scientific article indexed in Web of Science and/or Scopus database

Fingerprint Dive into the research topics of 'Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir(R) therapy: A case report'. Together they form a unique fingerprint.

Cite this